What is the typical rapid IV push dose of adenosine for acute SVT, and what is the expected effect?

Prepare for emergency medicine exams with our comprehensive test. Explore multiple choice questions, receive hints and explanations. Sharpen your knowledge and ensure success!

Multiple Choice

What is the typical rapid IV push dose of adenosine for acute SVT, and what is the expected effect?

Explanation:
Adenosine works by momentarily blocking conduction through the AV node, which is what often sustains a narrow-complex SVT. Because its half-life is extremely short, the drug must be given as a rapid IV push with a quick saline flush to reach the heart before it’s cleared. The typical approach is an initial rapid dose of six milligrams. If there is no response within about a minute or two, a second dose of twelve milligrams is given. A third dose is rarely needed. The expected effect is an abrupt relaxation of the AV nodal conduction which interrupts the reentrant circuit responsible for the tachycardia, usually converting it back to normal sinus rhythm within seconds. This dosing pattern—six milligrams first, then twelve milligrams if needed—best matches the standard rapid-acting regimen and the characteristic short-lived, AV-node–mediated effect of adenosine.

Adenosine works by momentarily blocking conduction through the AV node, which is what often sustains a narrow-complex SVT. Because its half-life is extremely short, the drug must be given as a rapid IV push with a quick saline flush to reach the heart before it’s cleared.

The typical approach is an initial rapid dose of six milligrams. If there is no response within about a minute or two, a second dose of twelve milligrams is given. A third dose is rarely needed. The expected effect is an abrupt relaxation of the AV nodal conduction which interrupts the reentrant circuit responsible for the tachycardia, usually converting it back to normal sinus rhythm within seconds.

This dosing pattern—six milligrams first, then twelve milligrams if needed—best matches the standard rapid-acting regimen and the characteristic short-lived, AV-node–mediated effect of adenosine.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy